Akero Therapeutics, Inc.

NASDAQ (USD): Akero Therapeutics, Inc. (AKRO)

Last Price

26.41

Today's Change

+0.06 (0.22%)

Day's Change

25.68 - 26.96

Trading Volume

436,967

Overview

Market Cap

1 Billion

Shares Outstanding

69 Million

Avg Volume

710,751

Avg Price (50 Days)

25.48

Avg Price (200 Days)

22.94

PE Ratio

-7.68

EPS

-3.44

Earnings Announcement

11-Nov-2024

Previous Close

26.35

Open

26.56

Day's Range

25.68 - 26.96

Year Range

11.25 - 53.77

Trading Volume

436,967

Price Change Highlight

1 Day Change

0.23%

5 Day Change

-2.76%

1 Month Change

11.53%

3 Month Change

14.73%

6 Month Change

-14.48%

Ytd Change

12.48%

1 Year Change

-46.98%

3 Year Change

9.54%

5 Year Change

18.06%

10 Year Change

44.16%

Max Change

44.16%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment